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The DNA damage response (DDR) is now known to play an important role in both cancer development and its
treatment. Targeting proteins such as ATR (Ataxia telangiectasia mutated and Rad3-related) kinase, a major
regulator of DDR, has demonstrated significant therapeutic potential in cancer treatment, with ATR inhibitors
having shown anti-tumour activity not just as monotherapies, but also in potentiating the effects of conventional
chemotherapy, radiotherapy, and immunotherapy. This review focuses on the biology of ATR, its functional role
in cancer development and treatment, and the rationale behind inhibition of this target as a therapeutic approach,
including evaluation of the progress and current status of development of potent and specific ATR inhibitors that
have emerged in recent decades. The current applications of these inhibitors both in preclinical and clinical
studies either as single agents or in combinations with chemotherapy, radiotherapy and immunotherapy are also
extensively discussed. This review concludes with some insights into the various concerns raised or observed with
ATR inhibition in both the preclinical and clinical settings, with some suggested solutions.1. Introduction: An overview of DNA damage response (DDR)
machinery in cancer
The integrity of human DNA is constantly subject to damage either by
exogenous exposure to radiation or genotoxic agents, or by endogenous
reactive and oxidative by-products of normal cellular metabolisms. This
damage, if not repaired or incorrectly repaired, becomes lethal to the cell
or organism (De Bont and van Larebeke, 2004; Jackson and Bartek,
2009). Constant and efficient repair of this DNA damage is therefore
essential and biologically significant in preventing cellular death and
many human diseases including cancer (Jackson and Bartek, 2009; Roos
and Kaina, 2006). Thus, considering the genomic threat posed by DNA
damage, cells respond to this DNA damage by activating a complex but
distinct network of signalling pathways collectively termed the DNA
Damage Response (DDR) that repair damage to constantly maintain the
integrity of the genome and prevent the development of diseases such as
cancer (Fig. 1).
The DDR comprises processes and mechanisms through which DNA
damage is detected and repaired to maintain genomic stability and
integrity, and this is significant to the survival and viability of a cell or
organism (De Bont and van Larebeke, 2004). DDR pathways are crucial to
both the development of cancers and their treatments, as cancer cells
with defective DDR mechanisms exhibit high sensitivity to certain ther-
apeutics, notably DNA damaging agents (Karnitz and Zou, 2015; Fong.A. Falconer).
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formation (Jackson and Bartek, 2009; Kandoth et al., 2013).
Genomic instability is a widely known hallmark of cancer, which may
occur as a result of dysfunctional and/or dysregulation of DDR mecha-
nisms (Hanahan and Weinberg, 2000, 2011; Negrini et al., 2010). For
example, in hereditary cancers such as breast cancer, genomic instability,
which drives these cancers, is known to result from mutations in DNA
repair genes such as BRCA 1/2 (Bartkova et al., 2005). Defects in DDR
mechanisms are generally known as major drivers of development in
most cancers (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005), such
that functional loss (mutation) and/or dysregulation of key DDR genes
and proteins are the primary molecular features of many cancers (Kan-
doth et al., 2013; Lavin, 2008). Such deficiencies in DDR either confer a
growth advantage on tumours, thereby breaking the proliferation barrier
posed by DDR and allowing the aggressive transformation of
pre-cancerous cells to malignant tumours (Gorgoulis et al., 2005; Bart-
kova et al., 2006), or they increase the risk of cancer development. For
example, women with mutated BRCA genes are more predisposed to
developing breast and ovarian cancers than those with non-mutated
genes (Pal et al., 2005; Levy-Lahad and Friedman, 2007). It is also
known, however, and has become more apparent recently that the
impairment of DDR mechanisms may significantly impact on the success
(or otherwise) of cancer treatments, especially DNA damaging therapies
such as cisplatin, irinotecan, gemcitabine, and ionizing radiation (IR)24 January 2021
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Fig. 1. DDR and cancer development. The presence of DNA damage either by
exogenous or endogenous agents triggers the functional mechanisms of DDR
leading to the rapid and efficient repair of DNA damage through cell cycle arrest
and delays, and in some cases, apoptosis of cells when DNA damages accumulate
beyond repair. This maintains genomic integrity which is critical for cell sur-
vival and viability. In contrast, DDR dysfunctions, which may be due to muta-
tions and/or dysregulation of DDR mechanisms, can lead to inefficient or
unrepaired DNA damage that in turn destabilise the genome of these cells.
Genomic instability induces various aberrant cellular behaviours leading to the
development of cancers.
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inducing DNA damage, which is cytotoxic to highly proliferating cells
(Johnson and Westcott, 2016). The response of cancer cells to such DNA
damage therefore critically determines the success of these treatments.
The inability of the cancer cells to efficiently and rapidly repair suffi-
ciently high levels of DNA damage due to their DDR impairments will
ultimately lead to cell death and hence account for the increased treat-
ment efficacy of these therapies.
This positive therapeutic impact of DDR impairment of cancer cells on
cancer treatment is mostly overcome by the inherent ability of tumours to
activate (or re-activate) DDR mechanisms as a strategic response to
escape the potentially lethal therapeutic effects of these anti-cancer
therapies, however (Woods and Turchi, 2013; Karnitz et al., 2005).
This perhaps explains the poor response and tumour resistance often
observed in most solid tumours with these agents in the clinic. For
example, tumour cells that have been shown to emerge as resistant to the
DNA-damaging agents (cisplatin and gemcitabine) after prolonged
treatments, are also accompanied by extremely high expression of DDR
genes and proteins (Bao et al., 2006; Oliver et al., 2010). These findings
clearly underscore the crucial role of DDR pathways in both the devel-
opment and treatment of cancers. DDR and its regulators have therefore
become attractive and promising strategic targets for novel cancer ther-
apy: the exploitation of these pathways can provide a platform to develop
novel anti-cancer drugs that can act as chemo- and/or radiosensitisers to
enhance the therapeutic response of current conventional
DNA-damaging anti-cancer therapies (Fong et al., 2009; Garrett and
Collins, 2011; Bornstein and Jimeno, 2016). Moreover, the interplay
between major DDR regulators in response to DNA damage creates a
‘synthetic lethality’ like dependency, where functional loss of DDR
components as observed in most tumour cells leads to a greater reliance
on the residual DDR factors to maintain viability and survival following
DNA damage (Kaelin, 2005; Reaper et al., 2011). Tumour cells are known
to exhibit severe and excessive DNA damage during tumourigenesis due
to oncogenic-induced replication stress and genomic instability, which
may trigger apoptosis or senescence of these cells if left unrepaired
(Hanahan and Weinberg, 2011; Bartkova et al., 2006). Thus, with most2
DDR key regulators, including ATM and P53, being mutated or dysre-
gulated in the majority of tumours (Karnitz et al., 2005), tumour cells are
more likely to rely on residual pathways such as the ATR pathway in
order to repair and survive this self-inflicted excessive DNA damage, and
its consequential cell death (Nghiem et al., 2001; Weber and Ryan, 2015;
Foote et al., 2015).
Targeting these residual DDR pathways may therefore be selectively
toxic to cancer cells with mutations in certain DDR genes. An example of
this ‘synthetic lethality’ concept is the inhibition of poly ADP-ribose
polymerase (PARP), a DNA damage repair enzyme, which has been
shown to be selectively lethal to cancer cells harbouring mutations in
some DDR genes, including BRCA1/2 (Fong et al., 2009; Bryant et al.,
2005; Farmer et al., 2005). This observation has led to the development
of PARP inhibitors olaparib, rucaparib and niraparib which are all
currently approved by the Food and Drug Administration (FDA) and
European Medicine Agency (EMA) for the treatment of ovarian cancers
(Bitler et al., 2017; Jiang et al., 2019). Olaparib and rucaparib have also
been approved by the FDA for the treatment of prostate cancer (BRCA
1/2 and ATM gene mutated) (National Cancer Institute Website, 2020),
with various other candidates including veliparib, talazoparib and flu-
zoparib at various stages of clinical development (Bitler et al., 2017;
Jiang et al., 2019; Wang et al., 2019).
These DDR response signalling pathways have in recent times gained
significant attention in cancer therapy, with various DDR proteins
including ATR, ATM, DNA-PK, CHK1, CHK2, Wee1, and PARP now all
considered promising targets for anti-cancer drug development (Jackson
and Bartek, 2009; Carrassa and Damia, 2017; Brown et al., 2017). With
the exception of PARP inhibitors (which have been successfully approved
for clinical use) inhibitors of other DDR proteins have yet to realise their
clinical potential (Brown et al., 2017). The ATR-CHK1 pathway, a major
pathway of the DDR machinery, is one of most (if not the most)
researched DDR pathways in cancer (Jackson and Bartek, 2009). Despite
over two decades of enormous efforts, an ATR inhibitor for cancer
treatment is yet to be clinically successful. In this review, we compre-
hensively discuss the functional role of ATR in DDR, particularly in
relation to cancer development and treatment, and focus on the pre-
clinical studies describing potential ATR inhibition in cancer therapy;
hence the rationale behind the development of ATR inhibitors for cancer
treatment. The progress and current status of all published ATR inhibitors
(13 at the time of writing) since the report of the first (Schisandrin B),
including the new generation of ATR inhibitors that has entered clinical
development, are also discussed. We conclude by offering some insights
into concerns that have been raised and reportedly observed following
use of ATR inhibitors in the clinic, and consider how these shortcomings
may be addressed so that this promising class of agent fulfils its potential.
1.1. Structure of ATR
ATR (Ataxia telangiectasia and Rad3 related protein) is a member of
the phosphatidylinositol 3-kinase-related kinase (PIKK) family of serine/
threonine protein kinases, which also includes ATM (Ataxia telangiec-
tasia mutated protein), DNA-dependent protein kinase (DNA-PK),
mammalian target of rapamycin (mTOR), suppressor of morphogenesis
in genitalia (SMG1) and transformation/transcription domain-associated
protein (TRRAP) (Cimprich and Cortez, 2008; Lempiainen and Halazo-
netis, 2009). Despite the lack of a kinase domain and activity of TRRAP
(McMahon et al., 1998), it is still considered a member of this family
since it shows high sequence similarities with other PIKK members
(Lempiainen and Halazonetis, 2009). The cellular functions of this PIKK
family are diverse, ranging from crucial roles in DDR (ATM, ATR and
DNA-PK), control of cell growth, proliferation, metabolism (mTOR and
ATM), nonsense-mediated mRNA decay (SMG1) and epigenetic regula-
tion of transcription (TRRAP) (Weber and Ryan, 2015; Lempiainen and
Halazonetis, 2009; Shiloh and Kastan, 2001), with their dysfunctions
implicated in range of diseases, including immunodeficiency, neurolog-
ical disorder and notably cancer (Jackson and Bartek, 2009).
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initiate and coordinate cellular responses to DNA damage and stress in
cooperation with other DDR proteins (Jackson and Bartek, 2009; Cim-
prich and Cortez, 2008). These responses include activation of cell cycle
checkpoints, DNA repair, transcriptional response and induction of
apoptosis if necessary (Sancar et al., 2004). ATR is a relatively large
protein at 300 kDa, and consisting of 2644 amino acids (Cimprich and
Cortez, 2008; Gately et al., 1998). Structurally, ATR kinase shares sig-
nificant similarities in its distinct domain architecture and sequence
homology with ATM (another apical regulator of the DDR pathways)
(Fig. 2), (Weber and Ryan, 2015; Lempiainen and Halazonetis, 2009;
Flynn and Zou, 2011; Bosotti et al., 2000) which suggests similarities in
the regulation mechanisms of these kinases (Cimprich and Cortez, 2008).
For example, both kinases are known to preferentially phosphorylate
serine or threonine residues followed by glutamine (SQ/TQ motif)
(Matsuoka et al., 2007). However, despite exhibiting a large degree of
similarity in most of their domains, the N-terminal domains of the two
kinases ATM and ATR, are observed to share low sequence homology,
and since members of the PIKK family are known to interact with distinct
regulatory partners (Flynn and Zou, 2011), it is believed that the
uniqueness of this N-terminal region is essential for differential associa-
tion with their distinct and relative adapter proteins and downstream
substrates (Cortez et al., 2001; Fernandes et al., 2005). For example, the
N-terminus of both ATM and ATR contain either a distinct protein
interacting domain or binding sites for Tel1 (TAN) (Seidel et al., 2008),
p53 and BRCA1 (Fernandes et al., 2005), and ATRIP (Cortez et al., 2001),
which are essential for the signalling of these kinases upon various types
of DNA damage.
Besides ATM, ATR has also been shown to share some structural
similarities and sequence homology with other DDR proteins, namely
DNA-PK and mTOR, particularly within their catalytic loop with a
conserved aspartate (D) residue that plays a key role in the kinase
functions these proteins (Menolfi and Zha, 2020).
1.2. Signalling and functions of ATR in DDR
Although ATM and ATR are known to share multiple functional and
structural similarities, as well as substrate phosphorylation specificity
(serine or threonine residues followed by glutamine), they are primarily
activated and respond to different types of DNA damage (Fig. 3). (Cim-
prich and Cortez, 2008) Whilst the activation of ATM kinase occurs in
response to DNA double-strand breaks (DSB), whichmay occur as a result
of either extrinsic IR exposure or intrinsic collapse of stalled replication
forks, ATR kinase is activated by the extensive presence of single-stranded
DNA structures (ssDNA) (Canman et al., 1998; van Gent et al., 2001;
Bakkenist and Kastan, 2003).
ATR is specifically activated in response to extensive single stranded
DNA structures (ssDNA), which may primarily arise from a stalled DNA
replication stress or other types of DNA damage, including resected DNAFig. 2. Schematic diagram of the domain structure of ATM and ATR. Known
structural domains are shown for each protein; FRAP–ATM–TRRAP domain
(FAT), FAT C-terminal domain (FATC), Phosphatidylinositol 3-kinase-related
kinase domain (PIKK), Tel1/ATM N-terminal motif (TAN), ATR interacting
protein (ATRIP), and UVSB PI3 kinase, MEI-41 and ESR1 domain (UME). ATM
and ATR consist of 3656 and 2644 amino acids respectively. (Adapted from
Weber and Ryan, 2015).
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DSB, crosslinks, base adduct and inhibition of DNA polymerases (Cim-
prich and Cortez, 2008; Flynn and Zou, 2011). Also, in contrast to
IR-induced activation of ATM, ATR is known to be activated by UV light
rather than IR, and it is primarily, if not entirely, responsible for the
initiation of the cellular response following UV-induced DNA damage
(Abraham, 2001). However, despite reports describing ATR inactivation
by IR, some studies have also suggested a delayed (compared to ATM
signalling) but rapid indirect activation of ATR by IR in the presence ATM
and Mre11 (Myers and Cortez, 2006). ATM and Mre11 are believed to be
stimulated by IR-induced activation of ATR through the conversion of
IR-induced DNA damage, normally DSB, into ssDNAwhich then activates
ATR (Myers and Cortez, 2006).
The stability, localisation, activation and functions of ATR require a
mutually dependent partner, namely ATR Interacting Protein (ATRIP)
(Cortez et al., 2001). ATRIP is considered to be an obligatory subunit of
the ATR kinase as no known phenotypic differences have been observed
in organisms upon loss of ATR or ATRIP (Cortez et al., 2001). It is
therefore suggested that ATR and ATRIP may exist and function as a
complex (Flynn and Zou, 2011). While it was mentioned earlier that
ssDNA activates the ATR pathway, it is actually the Replication Protein A
(RPA)-coated ssDNA that triggers the activation of ATR, as most ssDNAs
are rapidly coated by RPA once generated in cells (Flynn and Zou, 2011;
Cimprich and Cortez, 2008). RPA binds to ssDNA through multiple
oligonucleotide/oligosaccharide-binding folds (Marechal and Zou, 2015)
and coordinates the recruitment and localised ATR-ATRIP complex to the
sites of DNA damage and stress replication forks (Cortez et al., 2001).
RPA-ssDNA is also crucial in the recruitment of topoisomerase (DNA) II
binding protein 1 (TOPBP1), an activator of ATR in human cells
(Kumagai et al., 2006).
Once ATR is activated, it executes its cellular functions through the
phosphorylation and subsequent activation of many downstream sub-
strates involved in a wide range of cellular processes of which many are
not associated with DDR (Flynn and Zou, 2011). However, in response to
DNA damage, ATR functions principally via the phosphorylation and
activation of CHK1, the major downstream and best-studied target of
ATR (Bartek and Lukas, 2003). This stabilises stalled replication forks,
regulates origin firing, activates DNA damage repair and various check-
points of the cell cycle, leading to the maintenance of earlier cycle arrest
and induction of apoptosis or senescence when necessary (Cimprich and
Cortez, 2008; Toledo et al., 2008). The crucial roles for ATR in DDR occur
particularly at the S and G2 phases of the cell cycle (Sorensen et al.,
2003). After activation by ATR, CHK1 subsequently phosphorylates and
inhibits the activities of Cdc25A and Cdc25C to activate the intra
S-checkpoint and the G2/M checkpoint of the cell cycle respectively
(Sorensen et al., 2003; Sanchez et al., 1997; Xiao et al., 2003).
Cdc25 phosphatases are critical targets of the ATR signalling pathway
via CHK1 due to their essential roles in the regulation and progression of
the cell cycle (Flynn and Zou, 2011). CHK1 through the phosphorylation
of Cdc25Amediates the degradation of Cdc25A leading to the subsequent
inhibition of CDK1 and thus, inhibiting late replication origins during the
intra-S checkpoint (Sorensen et al., 2003; Xiao et al., 2003). The inhi-
bition of Cdc25C, through its phosphorylation by CHK1 also prevents the
entry of the cell into the mitotic phase of the cell cycle, thus blocking the
mitosis of cells with damaged DNA before DNA replication is completed
(Sanchez et al., 1997).
In addition to this, ATR is also known to activate the G1/S cell cycle
checkpoint through the phosphorylation and inhibition of Cdc25A by
activated CHK1, in response to UV light-induced DNA damage (Bartek
and Lukas, 2001). However, in conditions of continuous or excessive
DNA damage, p53 is phosphorylated by both ATR and CHK1 for either
continuous maintenance of the earlier cell cycle arrest or activation of
apoptosis if necessary (Bartek and Lukas, 2001; Taylor and Stark, 2001).
Unlike ATM, ATR has been shown to be an essential gene required for
normal cell cycle progression even in the absence of genotoxic stress, and
is important for cell viability and survival (Brown and Baltimore, 2000,
2003; Shechter et al., 2004). Total deletion of ATR is embryonically
Fig. 3. The signalling cascades of ATM and ATR. ATM
and ATR activate their distinct key mediator, CHK2
and CHK1 respectively, in response to respective DNA
damage, and through various downstream substrates
(p53, BRAC, Cdc25A, Cdc25c), which are commonly
shared among these kinases, execute their respective
functions to maintain the genomic integrity of cells.
ATR and ATM may interconvert depending on the
cellular content and the type of DNA damage to
compensate for one another.
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tissue homeostasis, depletion of progenitor cells in rapidly proliferating
tissues and premature aging in adult mice (Brown and Baltimore, 2003;
Ruzankina et al., 2007). Moreover, partial loss of ATR function in
humans, though not lethal, results in a rare genetic disorder, Seckel syn-
drome. This is a disease characterized by dwarfism, intrauterine growth
and mental retardation, severe microcephaly and a dysmorphic facial
feature (O'Driscoll et al., 2003; Karnitz and Zou, 2015; Alderton et al.,
2004). Cellular functions of ATM and ATR in response to DNA damage
are known to partially overlap though are not necessary redundant,
depending on the cellular context and type of DNA damage (Helt et al.,
2005). For example, although CHK1 is known to be the specific key
downstream target of ATR signalling, it can be also phosphorylated by
ATM in response to IR (Sorensen et al., 2003). ATR is also known to
phosphorylate, essentially, all downstream ATM-specific substrates such
that in ATM-deficient cells, ATR activation is sufficient to activate the
G1/S checkpoint - a principal function of ATM (Foote et al., 2015; Flynn
and Zou, 2011).
ATR and ATM, as master controllers of DDR, may function closely
together through their shared downstream targets, such that defects in
one signalling pathway may significantly be compensated by the other,
thus, ensuring efficient cellular response to various types of DNA damage
in order to ultimately safeguard the integrity of the genome (Abraham,
2001; Cimprich and Cortez, 2008; Shiloh and Kastan, 2001).
1.3. ATR as a therapeutic target for cancer
Although ATR has been established as an essential protein whose
functions are critical for both the viability and survival of cells (Brown
and Baltimore, 2000, 2003; Schoppy et al., 2012), several studies have
now demonstrated that the inhibition of functional kinase activity of ATR
in tumour cells may either increase the sensitivity of tumour cells to4
genotoxic agents and/or cell death by apoptosis or cellular senescence,
both of which have potential anti-tumour implications (Karnitz and Zou,
2015; Weber and Ryan, 2015).
The activity of ATR is crucial in all highly proliferative cells including
tumour cells, particularly during the S-phase of the cell cycle, due to the
replication stress associatedwith this phase of the cell cycle (Toledo et al.,
2008; Brown and Baltimore, 2000; Ruzankina et al., 2007). However, the
functions of ATRappear to be evenmore critical inmany tumour cells than
in normal cells, as tumour cells possess activated oncogenes such as ras,
myc, and cyclin E, which are known to disrupt the normal cell cycle
regulation, generating high replication stress as compared to normal cells
(Hanahan and Weinberg, 2011; Toledo et al., 2008). In response to
excessive replication stress, which ultimately generates high volumes of
ssDNA, cells are more prone to cell death than survival if damage is not
immediately repaired (Toledo et al., 2008). The ATR pathway is therefore
critical for the survival of tumour cells, with several reports showing that
inhibiting this DDR pathway is selectively toxic to tumour cells with high
oncogene-driven replication damage (Helt et al., 2005; Gilad et al., 2010;
Murga et al., 2011; Ferrao et al., 2012). For example, activation of the Ras
oncogenewith complete suppression of functional ATR has been shown to
aggravate oncogene-induced replication stress leading to tumour growth
arrest and substantial tumour cell death (Helt et al., 2005). Also, in
HPV-related cancers such as cervical cancer, the expression and activities
of oncoproteins such as E6 and E7 tends to increase the dependence of
these cancer cells on the ATR pathway for survival as they imbalance the
nucleotide pools for DNA synthesis, increasing the levels of replication
stress (Bester et al., 2011; Wieringa et al., 2016).
Moreover, the loss of ATM functions, which is a common feature of
most tumours, either through mutation of the ATM protein itself or its
associated downstream targets, particularly p53, renders tumour cells
defective at the G1 cell-cycle checkpoint as the ATM/p53 pathway is
principally responsible for the activation of this checkpoint (Bolt et al.,
Fig. 4. Chemical structures of caffeine and wortmannin, which are among the
early agents used in ATR inhibition studies.
Table 1





Schisandrin B ATR IC50 ¼ 7.25 μM Not reported
NU6027 ATR; Ki ¼ 0.1 μM
CDK2; Ki ¼ 1.3 μM
CDK1; Ki ¼ 2.5 μM
ATM homologs > 1.5
Dactolisib (NVP-BEZ235) ATR; IC50 ¼ 21 nM
ATM; IC50 ¼ 7 nM
DNA-PK; IC50 ¼ 5 nM
mTOR; IC50 ¼ 2 nM
PI3K; IC50 ¼ 2 nM
No selectivity
EPT-46464 ATR; IC50 ¼ 14 nM
mTOR; IC50 ¼ 0.6 nM
ATM > 40, DNAPK > 2.5
PI3K > 12
Torin 2 ATR; IC50 < 10 nM
mTOR; IC50 ¼ 0.25 nM
No selectivity
VE-821 ATR; IC50 ¼ 26 nM ATR homologs > 100
PI3K > 100
AZ20 ATR; IC50 ¼ 5 nM ATM, DNA-PK, PI3K >




ATR; IC50 ¼ 0.4 nM ATM, DNA-PK, PI3K >




ATR; IC50 ¼ 0.5 nM ATR homologs, PI3K >
30,000
Clinical – Phase I
M4344 (VX-803) ATR; IC50 < 0.2 nM ATR homologs, PI3K >
100
BAY1895344 ATR; IC50 ¼ 7 nM ATM > 200
DNA-PK > 40
PI3K > 400 mTOR  6
mTORcellular > 60
Clinical – Phase I & II
Berzosertib [M6620 (VX-
970)]
ATR; IC50 ¼ 0.2 nM ATR homologs, PI3K >
100
Ceralasertib [AZD6738] ATR; IC50 ¼ 4 nM ATR homologs, PI3K >
300
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renders cells more dependent on the intra-S-phase and G2/M check-
points, of which ATR principally mediates, for survival following DNA
damage (Cortez et al., 2001; Kastan et al., 1992). In recent times, ATR has
been demonstrated as an essential regulator of immune checkpoint
proteins such as PD-L1 in response to DNA damage, and with the
post-translational regulation of PD-L1 now established to be mainly by
ATR, the activation and inhibition of ATR clearly holds promising im-
plications in immunotherapy. For example, as ATR plays a major role in
PD-L1 regulation and with tumour cells evading T-cell mediated-killing
by the up-regulation of DNA-damage induced PD-L1 on these cells
(which is commonly observed with radiotherapy and DNA-damaging
chemotherapy), the targeting of ATR is reported to potentiate chemo-
and radiotherapy, in addition to promoting anti-tumour immune re-
sponses (Sun et al., 2018; Dillon et al., 2019).
In support of these findings, the ATR pathway has been reported to be
activated in the course of most cancer chemotherapy treatments (Cim-
prich and Cortez, 2008), perhaps as a responsive measure to repair DNA
damage induced by these agents, which consequently promotes tumour
survival and drug resistance. Initially, due to the essentiality of ATR for
cell viability and survival, its pharmacological inhibition was anticipated
to potentially not be tolerated in vivo. However, hypomorphic mice with
10% of the usual functional ATR levels were reported to be remarkably
normal, with preserved viability of highly proliferative tissues (Schoppy
et al., 2012). Furthermore, this significantly low level of ATR was suffi-
cient to induce synthetic lethality in oncogenic RAS-driven tumours,
suggesting a favourable therapeutic index as complete inhibition of ATR
may not be required to cause significant and selective toxicity in cancer
cells (Schoppy et al., 2012). ATR has therefore been long considered and
recognised as an attractive therapeutic target for anticancer therapy, with
this discovery generating a growing interest in the development of ATR
inhibitors.
2. ATR inhibitors
Despite several earlier proof-of-principle studies (Nghiem et al., 2001;
Sun et al., 2018; Dillon et al., 2019; Nishida et al., 2009; Wagner and
Kaufmann, 2010) that have profoundly demonstrated functional loss of
ATR as a potential sensitizer of cancer cells to conventional DNA
damaging chemotherapies, IR and immunotherapy, the development of
potent and specific small molecules targeting the ATR signalling pathway
as an anti-cancer therapy was initially focused on the development of
downstream CHK1 inhibitors rather than ATR kinase itself. The phar-
maceutical development of specific ATR inhibitors was so delayed that
several CHK1 inhibitors had already proceeded to clinical trials
(although none had proven successful) when the first specific ATR in-
hibitor was reported (Sarkaria et al., 1999; Rundle et al., 2017). This
delay was attributed to the earlier reported difficulties associated with
obtaining the pure active form of the kinase protein for in vitro studies
and its activating/interacting partners including ATIP, TopBP1 etc.
which are required for developing assays and thus the screening of po-
tential inhibitors (Rundle et al., 2017; Sarkaria et al., 1998). Addition-
ally, the lack of structural information about the ATR kinase (the crystal
structure of ATR still remains to be solved at the time of writing) is a
hindrance to a rational drug design approach for selective and specific
inhibitors.
Caffeine and wortmannin (a fungal metabolite) (Fig. 4) are among the
earliest agents used in the pioneering preclinical studies to demonstrate
the sensitisation potential of ATR inhibition (IC50 ¼ 1.1 mM and 1.8 μM
respectively) to IR and other genotoxic agents on cancer cells, although
these agents were also observed to inhibit multiple PIKKs (Nishida et al.,
2009; Wagner and Kaufmann, 2010). Nevertheless, despite the weak and
unspecific ATR inhibition demonstrated by these agents in vitro, and the
high in vivo toxicity (Karve et al., 2012; Ihle et al., 2004), the observed
chemo- and radio-sensitising effects of caffeine and wortmannin on
various cancer cells greatly encouraged those engaged in the quest to5
develop more potent and specific ATR inhibitors for cancer treatment.
Unfortunately, 20 years after these proof-of-principle studies, at the time
of writing, only thirteen ATR inhibitors have been reported at various
F.M. Barnieh et al. Current Research in Pharmacology and Drug Discovery 2 (2021) 100017stages of drug development (Table 1), with none approved clinically. It is
worth noting that four of these reported ATR inhibitors (Fig. 6), i.e.
AZD6738, M6620 (VX-970), BAY1895344 and M4344 (VX-803) have
progressed to phase I and II clinical trials in the last 8 years, however (see
Table 2).
In this review, known ATR inhibitors have been grouped into 2 cat-
egories: those in preclinical development (Fig. 5), and those agents that
have progressed to clinical evaluation (Fig. 6).2.1. ATR inhibitors in preclinical development
The first published ‘seemingly’ selective small molecule inhibitor of
ATR was Schisandrin B (ATR IC50 ¼ 7.25 μM) (Sarkaria et al., 1999).
Schisandrin B is an active ingredient of Fructus Schisandrae, the fruit of
the medicinal herb Schisandra chinensis (commonly known as the
magnolia berry) which was identified as an inhibitor of ATR activity
through a cell-based screen of herbal compounds. Schisandrin B was
observed to inhibit UV-activated G2/M and S-phase checkpoints and also
block the UV-induced ATR-dependent signalling pathway, which
enhanced the sensitivity of cancer cells to UV treatment. However,
despite the significant inhibition of ATR kinase activity by schisandrin B,
the cellular ATR potency of this agent was considered weak as theTable 2
Major highlights of ATR inhibitors in clinical development.
Agent Major Highlights
Phase I
M4344 (VX-803) — An orally administered ATR inhibitor developed by Vertex
— >100-fold selectivity against over 308 kinases, including A
— Preclinical data not extensively reported
— Synergistic activities observed with DNA-damaging agents
— Currently being evaluated either as a monotherapy or in co
BAY1895344 — An orally administered ATR inhibitor developed by Bayer
— >400-fold selectivity against PI3K kinases and 6-200-fold
— Relatively the least potent and selective ATR inhibitor amo
— Superior in vivo antitumor efficacy as monotherapy compa
— Profound synergistic effects observed in combination with
various cancer models
— Preliminary data from on-going clinical trials have reveale
have observed responses
Phase I & II
Berzosertib [M6620 (VX-
970)]
— An intravenously administered ATR inhibitor developed by
— An improved analogue of VE-821 (a preclinical ATR inhibi
— >100-fold selectivity against PI3K kinases and ATR homol
— First ATR inhibitor to enter clinical trials
— Has demonstrated strong chemo- and radio-sensitising abil
— Chemo-sensitising potential of this agent is more profound
— Highly synergistic effect also observed with other DDR inh
(olaparib)
— Currently being evaluated in at least 19 Phase I & II clinica
immunotherapy
— Data from some Phase I trials suggests the agent is well-tole
with no dose-limiting toxicities. Both dose-limiting and no
with cisplatin or gemcitabine
— Early disease responses including a complete response have
with its Phase I trials
Ceralasertib [AZD6738] — An orally administered ATR inhibitor developed by AstraZ
— An improved analogue of AZ20 (a preclinical ATR inhibito
— >300-fold selectivity against PI3K kinases and ATR homol
— As a monotherapy, significant tumour growth inhibition ha
with enhanced sensitivity observed in ATM- and p53-defic
— Highly synergistic cell killing activity observed in combinat
AZD1775), antimetabolites (gemcitabine), radiotherapy, an
— Synergistic effects with cisplatin are more profound in ATM
— AZD6738 has also been observed to boost the immunogen
immune cells and production of radiation-induced tumour
— In clinical trials, AZD6738 is well-tolerated in patients bot
though toxicities including haematological toxicities, immu
20% subjects
— Data from Phase I trial revealed both partial and complete
— Currently being evaluated in at least 25 Phase I & II clinica
immunotherapy
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observed sensitisation of UV-treated cancer cells occurred only at rela-
tively high concentrations (30 μM), which may lead to off-target inhi-
bition and systemic toxicities (Sarkaria et al., 1999). Additionally,
schisandrin B was observed to inhibit not only the phosphorylation of
ATR substrates at high concentrations but also substrates of ATM,
thereby revealing a lack of selectivity. It is noteworthy that although
schisandrin B was abandoned in its development as an ATR inhibitor,
other studies have described it as an effective dual inhibitor of P-glyco-
protein and multidrug resistance protein 1 (MRP1) (Sun et al., 2007), an
effective cardio-protective agent against doxorubicin-induced car-
diotoxicity (by enhancing glutathione redox cycling and inhibition of
MAPK/p53 signalling) (Xu et al., 2011; Thandavarayan et al., 2015), a
modulator of the NF-κB pathway in reducing cisplatin-induced toxicities
(Giridharan et al., 2012), and as a blocker of epithelial-mesenchymal
transition, hence reducing lung and bone metastasis (Liu et al., 2012).
These effects further illustrate the lack of target selectivity, however.
In 2011, 12-years after schisandrin B was described as a potential ATR
inhibitor, NU6027, a CDK2 inhibitor, was observed to be more potent
against ATR kinase activity (ATR Ki ¼ 0.1 μM) than its original intended
target (CDK2 Ki ¼ 1.3 μM) (Peasland et al., 2011; Arris et al., 2000).
Unlike schisandrin B, NU6027 was identified as a low micromolar in-
hibitor of ATR activity in cancer cells (IC50 ¼ 6.7 μM), with no observedPharmaceuticals (US) and Merck KGaA (Germany)
TR homologs (ATM, DNA-PK and mTOR)
and DDR inhibitors in a panel of cancer cell lines, both in vitro and in vivo
mbination with chemotherapy in patients with advanced solid tumours
AG (Germany)
against ATR homologs (ATM, DNA-PK and mTOR)
ng the currently clinically assessed ATR inhibitors
red to other ATR inhibitors (AZD6738 and M6620), due to its high plasma levels
DNA-damaging agents, DDR inhibitors, radiotherapy and even with hormone therapy in
d dose-limiting haematological toxicities, though patients with ATM defective tumours
Vertex Pharmaceuticals (US) and Merck KGaA (Germany)
tor)
ogs (ATM, DNA-PK and mTOR)
ities in multiple cancer models, both in-vitro and in-vivo
with Pt-based chemotherapy
ibitors, including CHK1 inhibitor (V158411), Wee1 (AZD1775) and Parp inhibitor
l trials, either as monotherapy or in combination with radio-, chemo- and/or
rated as a monotherapy, even at high doses (480 mg/m2) with a median half-life of 16h
n-dose limiting toxicities were observed in combination therapy, however, particularly
been observed with either monotherapy, or in combination with other cytotoxic agents
eneca (UK)
r)
ogs (ATM, DNA-PK and mTOR)
s been observed in multiple cancer models, including solid and haematological cell lines,
ient models
ion with DNA damaging agents (cisplatin, cyclophosphamide), DDR inhibitors (olaparib,
d even with immunotherapy
-deficient cells (10-17-fold increase) compared to ATM-proficient cells (2-fold increase)
ic effects of radiation, with a marked increase in antigen presentation, infiltration of
-derived cytokine production including CCL2, CCL5, CXCL10, and CXCL9
h as a monotherapy and in combination with carboplatin, olaparib, and durvalumab,
ne toxicities, nausea/vomiting, musculoskeletal chest pain and dyspnoea were evident in
responses in patients with advanced solid tumours
l trials, either as monotherapy or in combination with radio-, chemo- and/or
Fig. 5. Chemical structures of reported ATR inhibitors in preclinical development.
F.M. Barnieh et al. Current Research in Pharmacology and Drug Discovery 2 (2021) 100017inhibition of cellular ATM and DNA-PK even at high concentrations
(10 μM). This cellular inhibition of ATR by NU6027 was observed to
sensitise ovarian and breast cancer cells to various DNA-damaging
anti-cancer therapeutics, although this was more profound withFig. 6. The chemical structures of ATR inhibitors currently being evaluated in
Phase I & II cancer clinical trials.
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cisplatin (2-fold increase in potency) and hydroxyurea (3.2-fold
increase).
Significantly, ATR inhibition by NU6027 also demonstrated for the
first time a synthetic lethality with PARP inhibition (rucaparib), by
inhibiting homologous recombination (Peasland et al., 2011). Despite its
promise, NU6027 was ultimately not developed further due to a lack of
ATR selectivity over the wider kinase family. That said, the reported
observations with this agent, especially the observed synthetic lethality
of ATR inhibition with PARP inhibition and XRCC1 defects, both pro-
vided a solid foundation on which to build, as well as generating further
interest for the development of selective ATR inhibitors (Peasland et al.,
2011). NU6027 remains a useful experimental tool in ATR research to
this day.
With the tendency of small molecules cross-inhibiting ATR and its
homologs ATM, DNA-PK and mTOR, and the fact that the kinase activity
of ATR is restricted to the S/G2 phases of the cell cycle, cell-based
screening for specific and potent ATR inhibitors was considered prob-
lematic due to the greater chance of false positives that could result from
an indirect effect of the tested compound on the cell cycle (Rundle et al.,
2017; Toledo et al., 2011). Crucially, a novel cell-screening platform was
developed and reported in 2011 in which the measure of ATR activity
was assessed by quantifying the pan-nuclear phosphorylation of H2AX
(γH2AX), a process strictly dependent on ATR activity, thus overcoming
the limitations of false positives with earlier screening assays (Toledo
et al., 2011). Two compounds, NVP-BEZ235 and ETP-46464, each with
potent (Nanomolar) ATR inhibitory activity emerged from a pool of PI3K
inhibitors using this screening approach (Toledo et al., 2011).
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BEZ235, a dual PI3K/mTOR inhibitor (Maira et al., 2008), was already in
phase I/II clinical trials for advanced solid tumours (NCT00620594;
NCT01508104; NCT01658436: NCT01756118; NCT01658436) at the
time of its identification as a potent ATR inhibitor. NVP-BEZ235 was
reported to be highly active against ATR kinase itself (ATR IC50¼ 21 nM)
in cell-free assays, and also potent against ATR cellular activities (ATR
IC50 ¼ 100 nM). However, this compound was observed to also inhibit
activities of other ATR homologs at relatively low nanomolar concen-
trations: ATM (IC50 ¼ 7 nM) and DNA-PK (IC50 ¼ 5 nM). NVP-BEZ235
was therefore referred by the authors as an inhibitor of DDR, rather
than an inhibitor of ATR (Toledo et al., 2011). In view of this observation,
and in addition to an earlier report which described NVP-BEZ235 as a
potent radio-sensitizer for Ras-overexpressing tumours (Konstantinidou
et al., 2009) (an observation which is more likely to be linked to the
inhibition of ATR and its homologs rather than PI3K or mTOR inhibition)
the anti-tumour activity of NVP-BEZ235 was suggested to be due to a
potent effect on ATR activity rather its earlier reported PI3K/mTOR in-
hibition (Toledo et al., 2011). It is worth noting that the clinical devel-
opment of NVP-BEZ235 as an anti-cancer agent has been halted due to an
unexpected high degree of toxicity, and a lack of clinical efficacy
(Wise-Draper et al., 2017; Carlo et al., 2016; Fazio et al., 2016) which
may be due to a lack of knowledge of the potency of this compound on
DDR and particularly ATR, which was not considered in the rational
design of various clinical studies on this compound. NVP-BEZ235, now
renamed as RTB101, is currently being evaluated in mild or moderate
Parkinson's disease (resTORbio, 2019) although its clinical trials as a
selective inhibitor of TORC1 on respiratory infections and their associ-
ated diseases (NCT04139915; NCT03373903) were halted due to the
inability to meet the primary endpoint of the study (Kaeberlein, 2020).
ETP-46464, on the other hand, was more specific and potent against
ATR activity both in cell-free assays (ATR IC50 ¼ 14 nM) and cellular
assays (ATR IC50 ¼ 25 nM), exhibiting some level of ATR selectivity over
other ATR homologs; ATM (40-fold) and DNA-PK (2.5-fold) (Toledo
et al., 2011). This observation led to ETP-46464 being recognised as the
first highly potent and selective ATR inhibitor to be reported. Unfortu-
nately, due to the poor pharmacological properties of ETP-46464 in mice,
its further development as an anti-cancer therapy was abandoned
(Toledo et al., 2011). Other potent, but unselective, ATR inhibitors have
also been reported, for example Torin-2 (Liu, 2011, 2013). Torin-2, a
highly potent mTOR inhibitor (IC50 ¼ 0.25 nM) was reported to inhibit
ATR and the activities of homologs in the low nanomolar range (IC50 <
10 nM) (Liu et al., 2013). The frequent observations of these highly
potent mTOR inhibitors (NVP-BEZ235, ETP-46464 and Torin-2) exhib-
iting activities against other PIKK family members, particularly against
those kinases involved in the DDR pathways (ATR and ATM) known to be
essential for tumour growth (Gilad et al., 2010), seems to support the
notion that the reported anti-tumour activity of these agents may be due
to inhibition of these DDR kinases rather than mTOR inhibition (Weber
and Ryan, 2015; Toledo et al., 2011).
With the discovery of a potent and selective ATR inhibitor still
remaining elusive, Vertex Pharmaceuticals was reported to have identi-
fied a high throughput screen (HTS), which solved the earlier limitations
of good, well-characterized chemical tools that hindered the develop-
ment of potent and selective ATR inhibitors (Rundle et al., 2017; Charrier
et al., 2011). The nature of this HTS providing a combination of
structure-activity relationship (SAR) studies and homology modelling led
to a better understanding of the interactions of potential inhibitors with
the ATR active site (Charrier et al., 2011), knowledge which is crucial for
rational drug design of potent, specific and selective inhibitors.
This HTS campaign led to the exciting discovery of the first series of
potent and selective ATR inhibitors by Vertex Pharmaceuticals, of which
VE-821 was identified as potent (ATR IC50 ¼ 26 nM) in cell-free assays,
but with more desirable selectivity (>100-fold) over ATR homologs
ATM, DNA-PK andmTOR and other kinases (Reaper et al., 2011; Charrier
et al., 2011). VE-821 was shown to strongly inhibit the phosphorylation8
of H2AX and CHK1, known markers of ATR activity, and also demon-
strated a strong synergy with radiotherapy and with various genotoxic
chemotherapeutics including gemcitabine, camptothecin, etoposide,
cisplatin and carboplatin when evaluated in a panel of different cancer
cells (Reaper et al., 2011; Prevo et al., 2012; Huntoon et al., 2013). This
synergetic effect was most marked with cisplatin and carboplatin (DNA
crosslinking agents), however. The apparent potency of cisplatin was
observed to increase more than 10-fold with VE-821 in colon cancer cells
with defective ATM signalling, for example (Reaper et al., 2011). This
observation provided direct support to the earlier reported synthetic
lethality interaction between ATR and the ATM-p53 pathway in cancer
cells, such that cancer cells with defective ATM signalling are more
reliant on ATR for survival fromDNA damage (Reaper et al., 2011; Cortez
et al., 2001; Kastan et al., 1992). Also, in ovarian cancer cells with
depleted BRCA 1/2 or BRCA mutations (defective homologous recom-
bination, HR), VE-821 was observed to further sensitise these cells not
only to DNA damaging agents like cisplatin, but also to the PARP in-
hibitor, veliparib (Huntoon et al., 2013). In addition to these
chemo-sensitisations, VE-821 was also shown to increase the sensitivity
of various cancer cells to IR-induced cytotoxicity, regardless of the
tumour type (Prevo et al., 2012; Pires et al., 2012). Interestingly, the
observed radio-sensitisation effect of this agent was even more profound
with hypoxic cancer cells (0.02–2.0% O2 concentration), as the pres-
ence of VE-821 was observed to sensitise radio-resistant hypoxic cancer
cells to radiotherapy (Prevo et al., 2012; Pires et al., 2012). Hypoxia is a
common feature of most solid tumours, inducing replication arrest even
in the absence of DNA (Hammond et al., 2002). In response to replication
stress, tumour cells activated their DDR pathways, which have been
associated with the chemo- and radio-resistance of hypoxic cancer cells
(Woods and Turchi, 2013; Sprong et al., 2006; Pires et al., 2010). Hyp-
oxic cancer cells are more radio-resistant (2.5-3-fold), and hence the
sensitisation of these cells by VE-821 through its ATR inhibition repre-
sented a major addition to the efficacy of radiotherapy. Even more
importantly, VE-821 as monotherapy was shown to selectively induce
cell death in cancer cells, but not normal cells. This again indicates the
reliance of cancer cells on the ATR pathway for survival (Reaper et al.,
2011; Pires et al., 2012). Unfortunately, despite this early promise,
VE-821 was not progressed further, with no in vivo data published.
However, the optimised analogue VE-822 (VX-970), with increased po-
tency and selectivity against ATR (Fokas et al., 2012) was developed
further and is currently in phase II clinical trials (see below, section 2.2).
VE-821 remains a valid template for designing and evaluating novel in-
hibitors of ATR and also in understanding the significance of ATR sig-
nalling in various cancers (Gorecki et al., 2020; Middleton et al., 2018;
Alsubhi et al., 2016; Al-Subhi et al., 2018).
In 2012, AstraZeneca discovered a hit through an HTS study of its
previously describedmTOR inhibitors series. The compoundwas over 10-
fold more potent against ATR (IC50 ¼ 30 nM) compared to the originally-
intended targetmTOR (IC50¼ 330 nM), and about 100-fold selective over
ATR homologs and PI3K kinases (Finlay et al., 2012; Foote et al., 2013).
This hit compoundwas optimised into AZ20, amore potent ATR inhibitor
(ATR IC50 ¼ 5 nM) with improved selectivity (>600-fold) over ATR ho-
mologs DNA-PK and ATM, and PI3Kα kinases, although this agent was
observed to have retained some residual inhibitory potency against the
recombinant mTOR enzyme (8-fold-selectivity) (Foote et al., 2013). In
vitro, AZ20 inhibited the activity of ATR in a concentration-dependent
manner, including phosphorylation of its primary substrate CHK1, with
prolonged exposure of AZ20 increasing γH2AX pan-nuclear staining
(replication stress), which is indicative of ATR inhibition (Foote et al.,
2013; Jacq et al., 2012). AZ20 also showed cytotoxic activity as a single
agent, and profoundly so in combinationwith the selectiveATM inhibitor,
KU-60019, in various cancer cells, and at a tolerated dose (50mg/kg once
daily and 25 mg/kg twice daily). AZ20 was shown to induce significant
tumour growth inhibition in LoVo (human colorectal cancer) xenografts
(ATM-deficient) in vivo (Foote et al., 2013; Jacq et al., 2012). It is worth
noting that AZ20 was the first ATR inhibitor to be reported with in vivo
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clinical development of AZ20 was halted due to poor solubility (10 μM
aqueous solubility at pH 7.4 in phosphate buffer) and CYP inhibition
(CYP3A4), which raised concerns of potential drug-drug interactions (the
CYP3A family is themajormetabolic enzyme formanydrugs) (Foote et al.,
2013). AZ20 was later optimised to AZD6738, which is currently being
evaluated in phase II clinical trials (see below, section 2.2).
In 2014, a group at Novartis also reported the identification of an ATR
inhibitor from a tetrahydropyrazolo[1,5-a]pyrazines series with potency
in a cell free assay (ATR IC50 ¼ 0.4 nM), and in a cellular assay (ATR IC50
¼ 0.037 μM)with 4000 to 10,000-fold selectivity over ATM, DNA-PK and
PI3Kα kinases, and about 100-fold selectivity over mTOR (Barsanti et al.,
2015a). This novel, potent and selective ATR inhibitor was discovered
through an optimisation campaign of an HTS hit, a low nanomolar dual
ATR and PI3Ka inhibitor (ATR IC50 ¼ 26 nM; PI3Ka IC50 ¼ 9 nM), using
PI3Kα mutants as an ATR crystal structure surrogate in addition to ATR
homology modelling. Unfortunately, despite this agent possessing
acceptable potency, selectivity, aqueous solubility (37 μM aqueous sol-
ubility at pH 7.4 in phosphate buffer) and bioavailability (F ¼ 64%), it
demonstrated time-dependent inhibition of CYP3A4 activity (Kinact/Ki ¼
0.028 μl/min/pmol), which raised concerns about potential drug-drug
interactions (DDIs) and safety, thereby halting its progression (Barsanti
et al., 2015a). That said, this compound is arguably the most potent and
selective ATR inhibitor to be reported (particularly over ATM, DNA-PK
and PI3Kα kinases). The full extent of its preclinical data (both in vivo
and most in vitro profiles) is unfortunately yet to be reported.
A year later, this same group from Novartis reported another highly
potent (ATR IC50 ¼ 0.5 nM), selective (>30,000-fold over ATR homo-
logs) and soluble (>2400 μM aqueous solubility at pH 7.4 in phosphate
buffer) azabenzimidazole derivative as an ATR inhibitor, this time devoid
of any CYP3A4 and hERG liabilities (Barsanti et al., 2015b). This agent
was reportedly discovered through modification of the core of a
morpholino-imidazopyrimidine hit identified through a combined vir-
tual screening and HTS campaign using a diverse subset of a Novartis
compound collection. However, despite the potency of this
morpholino-imidazopyrimidine hit against ATR (IC50 ¼ 96 nM), and
selectivity (>1000-fold) over ATR homologs, it harboured some phar-
macokinetics and CYP3A4 concerns (Barsanti et al., 2015b). Hence, the
modification of this hit into a potent and safer azabenzimidazole deriv-
ative ATR inhibitor. Unfortunately, this promising azabenzimidazole
derivative ATR inhibitor demonstrated poor bioavailability (F ¼ 7.5%)
probably due to low membrane permeability and efflux, although a
reasonable i. v. pharmacokinetics profile was observed. The progress of
this compound is yet to be reported (Barsanti et al., 2015b).
2.2. ATR inhibitors that have progressed to cancer clinical trials
2.2.1. Berzosertib (M6620; VX-970; VE-822)
Berzosertib is the first ATR inhibitor to be evaluated in humans, with
the first participant enrolled in a clinical study on December 10, 2012
(NCT02157792), about 13 years after the first selective ATR inhibitor
was reported (Sarkaria et al., 1999). Initially discovered and developed
by Vertex Pharmaceuticals as VE-822 (VX-970), an improved analogue of
VE-821 (a potent and selective ATR inhibitor, which lacked the drug-like
properties required for its progression as a clinical candidate), this agent
has now been acquired by Merck KGaA, Germany, for further clinical
development after exhibiting some preliminary clinical potential in a
phase I trial (NCT02487095) (Thomas et al., 2017).
M6620 is a highly potent and selective ATR inhibitor, inhibiting ATR
activity both in cell free assays (ATR IC50¼ 0.2 nM) and in cellular assays
(ATR IC50 ¼ 19 nM) with over >100-fold selectivity over DNA-PK, ATM,
and other PI3Kα kinases, in addition to its improved solubility (aqueous
solubility of 52 μM) and pharmacokinetic properties compared to its
precursor, VE-821 (Fokas et al., 2012; Knegtel et al., 2019).
Beginning with Fokas et al. (2012), the radiosensitising and chemo-
sensitising potentials of M6620 (VX-970) have been widely studied in9
multiple preclinical models. For example, in PDAC pancreatic cancer cells
and xenografts, VE-822 was shown to be a strong sensitizer for radio-
therapyandchemotherapyboth in vitroand in vivo, such that the efficacyof
radiotherapy and chemo-radiotherapy in pancreatic tumour xenografts
was profoundly enhanced in combination with VE-822 (Fokas et al.,
2012). Interestingly, although VE-822 attenuated ATR signalling in
normal cells, the observed VE-822-enhanced cytotoxicity of radiotherapy
and chemotherapywas selective to cancer cells but not normal cells (Fokas
et al., 2012). Also, in a panel of NSCLC cell lines, similar observationswere
reported (Hall et al., 2014). In this study, VX-970 was shown to strongly
potentiate the cytotoxic effects of various DNA damaging drugs including
cisplatin, oxaliplatin, gemcitabine, and etoposide selectively in lung
cancer cell lines but not normal cells (Hall et al., 2014).
Consistent with previous reports on other ATR inhibitors, the syner-
gistic effects of VX-970 were more profound with cisplatin as compared
to other DNA damaging drugs, with the observed chemo-sensitivity more
favourable in cells deficient in p53 (though no significant correlations
were observed with p53 status) (Hall et al., 2014). Also, in a panel of 7
human patient-derived lung tumour xenografts, VX-970 was observed to
significantly regress and delay tumour growth in six of these models in
combination with cisplatin, even at VX-970 doses known to lack efficacy
as a monotherapy, and in tumour models shown to be non-responsive to
cisplatin monotherapy (Hall et al., 2014). Again in another study, VX-970
was demonstrated to be highly synergistic with cisplatin and etoposide in
treatment-resistant SCLC models, such that VE-VX-790 in combination
with cisplatin was more efficacious than a combination of cisplatin with
etoposide both in vitro and in vivo (Nagel et al., 2019). Strikingly, the
combination of VX-790 and cisplatin was reported to not only profoundly
inhibit tumour growth in these SCLC mouse models, but also improved
the survival of these mice (Nagel et al., 2019). These data were a strong
pointer towards possible clinical success as a chemo-sensitizer of DNA
damaging agents in lung cancer patients. Interestingly, further studies
have since demonstrated the chemo- and radio sensitivity potential of
VX-970 in a range of different cancers, including oral (Leszczynska et al.,
2016; Shi et al., 2018), colon (Combes et al., 2019), brain (Chen et al.,
2018) gastric (Yan et al., 2018), triple negative breast (Tu et al., 2018)
and various paediatric solid tumours (Kurmasheva et al., 2018), in
addition to lung cancers. For example, the cytotoxic activity of irinotecan
(Josse et al., 2014), and Pt-based chemotherapy (Combes et al., 2019)
has been shown to be potentiated by VX-970 without additional toxicity
in colon cancers, including in treatment-resistant models. Furthermore,
the combination of VE-822 and oxaliplatin was observed to significantly
promote antitumor T-cell responses, with increased survival in mouse
models, just as reported with inhibitors of the ATR signalling (Combes
et al., 2019). Also, in oesophageal tumours, M6620 was shown to
significantly inhibit tumour growth in combination with cisplatin, car-
boplatin and radiation in vitro and in vivo (Leszczynska et al., 2016; Shi
et al., 2018). It is noteworthy that although the chemosensitising ability
of M6620 has been shown to be profound with conventional cytotoxic
chemotherapy (particularly Pt-based chemotherapy), highly synergistic
effects have also been reported in combination with other DDR-related
pathway inhibitors, including CHK1 inhibitor V158411,134 WEE1 in-
hibitor AZD1775,135 and PARP inhibitor olaparib (Schmitt et al., 2017).
The ability of VX-970 and other ATR inhibitors to potentiate the cyto-
toxicity of other DDR pathway inhibitors has been attributed to the
observation that cancer cells activate alternative DDR pathways, in
particular ATR, to counter the effects of this inhibition (Massey, 2016).
Thus by inhibiting ATR kinase in addition to these other DDR pathways,
the cytotoxic effects of these inhibitors are fully maximised. For example,
in AML cells, the combination of AZD1775 and VX-970 has been shown
to exhibit synergistic anti-leukemic activity, with AZD1775 increasing
VE-822-induced DNA double-strand breaks, thereby enhancing
VE-822-induced cell apoptosis and inducing DNA damage and cell cycle
arrest (Qi et al., 2019).
Based on this highly promising preclinical data, M6620 has entered at
least19registeredphase I and II clinical trials since the start of itsfirst trial in
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committed to evaluating M6620 in combinations: with radiotherapy
(NCT02589522; NCT04052555), with chemotherapy including DNA-
damaging agents; topotecan, cisplatin, carboplatin, gemcitabine, irinote-
can, paclitaxel, doxorubicin, docetaxel and capecitabine (NCT02157792;
NCT03896503; NCT03641313; NCT03517969; NCT02627443;
NCT02595931; NCT02595892; NCT02567409; NCT02487095), with
PARP inhibitor veliparib (NCT02723864), with angiogenesis inhibitor
bevacizumab (NCT03704467) chemo-radiotherapy (NCT03641547;
NCT02567422), andevenwith immunotherapyavelumab(NCT04216316)
in various metastatic and refractory solid tumours. Two clinical trials
(NCT03309150; NCT03718091) are assessingM6620 as amonotherapy in
advanced and selected solid tumours.
The majority of these trials are still active and recruiting, with full
data of the two completed trials (NCT02157792; NCT03704467) yet to
be reported, therefore the full clinical potential of M6620 is not known.
However, the phase I arm of a single phase I/II trial (NCT02487095) has
been fully reported (Thomas et al., 2018). In this trial, 21 patients with
advanced solid tumours (with defective ATM-p53 signalling) were
enrolled to assess the tolerability, safety, and antitumor activity of
M6620 in combination with topotecan. This combination was generally
well-tolerated, even at the highest planned dose level (topotecan 1.25
mg/m2, days 1–5; M6620 210 mg/m2, days 2 and 5). Unfortunately, the
trial was reported to be associatedwith various grade 3/4 haematological
toxicities, including anaemia, lymphopenia, leukopenia, neutropenia,
thrombocytopenia and nausea. The observed toxicity profile of this
combination was dose-limiting and largely mirrored that of topotecan
monotherapy. The trial also provided some promising clinical activity,
with 2 partial responses (18 months,  7 months), 7 stable disease
responses (ranging from 3 to 12 months; median, 9 months) and more
interestingly, 3 out of 5 patients with platinum-refractory SCLC also
exhibiting a partial response (7 months) or stable disease responses (10
and 6 months) (Thomas et al., 2018). Based on this clinical activity in
platinum-refractory SCLC, a new randomised phase II trial has been
initiated for this combination in SCLC cancer and small cell cancers
outside of the lungs (NCT03896503).
In addition to this report, preliminary data from 5 different arms of a
just-completed single trial (NCT02157792) have also been separately
presented, albeit in the form of conference abstracts (Yap et al., 2015;
Shapiro et al., 2016; O'Carrigan et al., 2016; Plummer et al., 2016;
Plummer et al., 2018). In all these reports, M6620 as a monotherapy or in
combination with carboplatin (Yap et al., 2015; O'Carrigan et al., 2016),
or with cisplatin (Shapiro et al., 2016), or with gemcitabine (Plummer
et al., 2016, 2018), in various advanced solid tumours was well-tolerated,
although the maximum tolerated dose in the case of the combination
with cisplatin or gemcitabine was not reached due to dose-limiting
haematological toxicities, including grade 3 drug hypersensitivity, and
treatment-emergent adverse events (Shapiro et al., 2016; Plummer et al.,
2016, 2018). Common non-dose-limiting toxicities included fatigue,
nausea, cytopenias, hypotension and myelosuppression. M6620, how-
ever, was best tolerated as a monotherapy even at 480 mg/m2, with no
dose-limiting toxicities or drug-related G3-4 adverse effects observed
(Yap et al., 2015). The median half-life of M6620 also was determined as
16 h, with no accumulation (Yap et al., 2015; Shapiro et al., 2016;
Plummer et al., 2016), with evidence of target modulation and
anti-tumour responses with either M6620 monotherapy, or in combina-
tion with other cytotoxic agents. For example, a RECIST complete
response (19þ months) was observed with M6620 as monotherapy (60
mg/m2) in an advanced colorectal cancer patient with a tumour with
confirmed loss of ATM (Yap et al., 2015; O'Carrigan et al., 2016). In
addition to this, stable disease was also observed in 4 other patients with
M6620 alone (11–17.4 weeks), in 8 patients with M6620 þ carboplatin
(5þ to 20þ weeks) (Yap et al., 2015), and in 18/33 patients with M6620
þ gemcitabine (Plummer et al., 2018). The combination of M6620 with
cisplatin also led to partial response in 4/28 patients including 3 patients
with platinum-resistant/refractory tumours (mesothelioma, ovarian and10TNBC), and a neuroendocrine prostate cancer patient (Shapiro et al.,
2016). Fortunately, after 8 years of recruiting, the full trial
(NCT02157792) has now been completed (March 11, 2020) with 200
participants, and the publication of this data is currently eagerly awaited.
Hopefully this data will reveal the true clinical potential of VX-970 either
as a monotherapy or in combination with chemotherapy and radio-
therapy in these advanced solid tumours.
2.2.2. Ceralasertib (AZD6738)
Ceralasertib (developed by AstraZeneca), an improved sulfoximine
morpholinopyrimidine analogue of AZ20, is highly potent against ATR
activity both in cell free assays (ATR IC50 ¼ 4 nM) and in cellular assays
(ATR IC50 ¼ 74 nM) with improved selectivity (300-fold) over ATR ho-
mologs DNA-PK, ATM, mTOR and other PI3Kα kinases (Jones et al.,
2013; Guichard et al., 2013; Foote et al., 2018). More importantly, this
orally-administered ATR inhibitor exhibits improved aqueous solubility
(661 μM at pH 7.4 in phosphate buffer) and bioavailability, and is devoid
of the CYP3A4 time-dependent inhibition observed with AZ20 (Foote
et al., 2018). Based on very promising pre-clinical data, AZD6738 was
first admitted to a clinical trial in 2013 (NCT01955668), and is currently
being assessed in various phase I and II clinical trials.
Preclinically, AZD6738 has been extensively studied, and is still being
studied, in various tumour models both as a single agent, and in com-
bination with DNA damaging agents (including cisplatin, cyclophos-
phamide etc), PARP inhibitors (olaparib), antimetabolites (gemcitabine),
radiotherapy, and even immunotherapy. (Jones et al., 2013; Guichard
et al., 2013; Foote et al., 2018; Kim et al., 2017; Vendetti et al., 2015,
2018). As a single agent, AZD6738 was demonstrated to cause significant
tumour growth inhibition of ATM- and p53-deficient cells, both in vitro
and in xenograft models in vivo. AZD6738 was observed to increase the
accumulation of high volumes of unrepaired DNA damage in these
ATM-deficient cells, leading to cell death due to mitotic catastrophe
(Kwok et al., 2015). Also, AZD6738 has been demonstrated to signifi-
cantly inhibit cancer cell growth, with profound sensitivity in cells with
ATM-pathway defects when used as a single agent across different panels
of cancer cell lines in vitro (Guichard et al., 2013). In a LoVo xenograft
model (ATM-deficient) in vivo, AZD6738 achieved near complete tumour
growth inhibition at well-tolerated doses, although this observation was
absent in an HT29 xenograft model (ATM-proficient) despite the sensi-
tivity of these cells to the drug in vitro (Guichard et al., 2013; Foote et al.,
2018). AZD6738 was additionally shown to induce cell death and
senescence in a panel of non-small cell lung cancer (NSCLC) cells, and
other cancer cell lines in vitro, regardless of p53/ATM status (Vendetti
et al., 2015; Dillon et al., 2017). Similar observations have been reported
in a panel of human breast cancer cell lines (Kim et al., 2017). Moreover,
in gastric cancer cells with ATM deficiency, AZD6738 was shown to
induce synthetic lethality in this model both in vitro and in vivo (Min et al.,
2017). Also, in another study, the analysis of pancreatic ductal adeno-
carcinoma (PDAC) samples revealed at least one genetic alteration in
approx. 93% of these cases, which was responsible for the sensitivity of
these cells to this agent. The phenomenon of synthetic lethality may
account for this observation (Wallez et al., 2018).
Despite the promising data associated with use of AZD6738 as a
monotherapy, particularly in ATM-deficient cancer cells as summarised
above, the biggest clinical potential for this agent across a variety of
tumour types is perhaps in combination with other therapies. It has
demonstrated strong synergy with various classes of chemotherapy and
radiotherapy. (Vendetti et al., 2015, 2018; Dillon et al., 2017; Wallez
et al., 2018; Bukhari et al., 2019; Jin et al., 2018). For example, in NSCLC
cell lines, AZD6738 has been shown to potentiate the cytotoxicity of
cisplatin and gemcitabine regardless of their ATM kinase signalling sta-
tus. However, in the ATM-deficient subset of these NSCLC cell lines,
AZD6738 was seen to potently synergize with cisplatin, inducing rapid
cell death (Vendetti et al., 2015). For example, the synergistic effect of
AZD6738 (1 μM) on cisplatin sensitivity was more profound (10-17-fold
increase) in ATM-deficient cells (shRNA ATM knockdown H460 and
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(H460 and A549 wild type cells), with an approx. 2-fold increase (Ven-
detti et al., 2015). Also, in both ATM-proficient (H460) and
ATM–deficient (H23) lung cancer xenografts in vivo, the combination of
AZD6738 and cisplatin was well-tolerated and strongly inhibited tumour
growth; by approx. 76% in ATM-proficient and 85% in ATM-deficient
xenografts, with some mice strikingly demonstrating complete tumour
resolution despite the fact that these models had shown no response to
cisplatin alone (Vendetti et al., 2015). In another study, AZD6738 in
combination with carboplatin or cyclophosphamide was also
well-tolerated, exhibiting anti-tumour growth activity and regression
(Guichard et al., 2013). Similar synergistic observations have also been
reported with AZD6738 in combination with gemcitabine in pancreatic
ductal adenocarcinoma (PDAC) both in vitro and in vivo (Wallez et al.,
2018). In a panel of both mouse and human PDAC cell lines, this com-
bination was shown to synergistically inhibit cell growth, even with cells
which were shown to be highly resistant to both drugs alone, in vitro. The
combination was also shown to induce tumour regression in PDAC
tumour models in vivo, with a significant improvement in survival
observed at well-tolerated doses (Wallez et al., 2018). Similarly to the
reported chemo-sensitisation potential of AZD6738, radio-sensitisation
has also been extensively demonstrated both in vitro and in vivo (Dillon
et al., 2017, 2019; Vendetti et al., 2018). For instance, in multiple panels
of cancer cell lines AZD6738 was shown to uniformly potentiate the
cytotoxic activity of radiation, even at clinically relevant doses, regard-
less of the p53 and/or BRCA status, both in vitro and in vivo models
(Dillon et al., 2017). In these models, AZD6738 was observed to inhibit
HR, abrogate radiation-induced G2 cell-cycle checkpoint arrest and
promote the generation of acentric dysfunctional micronuclei due to
aberrant mitosis and mitotic catastrophe (Dillon et al., 2017). Remark-
ably, the synergistic effects of AZD6738 have recently been shown not to
be limited to cytotoxic agents or radiotherapy, but also to other molec-
ularly targeted small molecule agents, such as AZD1775 (Wee1 inhibi-
tor), olaparib (PARP inhibitor), acalabrutinib (Bruton's tyrosine kinase
inhibitor) (Guichard et al., 2013; Bukhari et al., 2019; Jin et al., 2018;
Clack et al., 2015). For example, in triple-negative breast cancer cells, the
growth inhibition activity of AZD1775 was observed to be strongly
potentiated by AZD6738, both in vitro and in vivo. The combination of
AZD1175 and AZD6738 was observed to strongly induce mitotic catas-
trophe, ultimately leading to cell death and also inactivated
RAD51-mediated homologous recombination, which enhanced the
sensitivity of these cells to cisplatin and a PARP inhibitor, independent of
BRCA status (Jin et al., 2018). Also, on a panel of breast cancer cell lines
and cancer stem cells, this combination has been shown to exhibit highly
synergistic cytotoxicity (Bukhari et al., 2019). Lastly, the influence of
AZD6738 on tumour immunology and its implication in immunotherapy
has also been reported. In a colorectal cancer model, AZD6738 was re-
ported to strongly impact CD8þ T cell–dependent immune responses
following radiation, and to potentiate CD8þ T cell–dependent
anti-tumour responses in these tumour models, with immunologic
memory generated in complete responder mice (Vendetti et al., 2018).
Interestingly, AZD6738 was also shown to attenuate the up-regulation of
radiation-induced PD-L1 expression on tumour cells, and strikingly de-
creases tumour-infiltrating regulatory T cells, which perhaps contributes
to the highly synergetic effect observed with radiation and AZD6738 in
combination (Vendetti et al., 2018). In another recent study, adminis-
tration of AZD6738 following radiation in HPV-driven malignancies was
also observed to boost the immunogenic effects of radiation, with a
marked increase in antigen presentation, infiltration of immune cells
including CD8þ, CD3þ, NK cells, and production of radiation-induced
tumour-derived cytokine production, such as CCL2, CCL5, CXCL10, and
CXCL9 (Dillon et al., 2019).
Underpinned by this large volume of promising pre-clinical data,
AZD6738 is currently being assessed in no fewer than 25 phase I and II
clinical trials (www.clinicaltrial.gov). In phase I clinical trials, AZD6738 is11being evaluated as a monotherapy in haematological cancers
(NCT01955668, NCT03770429) and in solid refractory tumours
(NCT02223923, NCT03022409), but also in combination with radiation,
chemotherapy and immunotherapy: radiation (NCT02223923), carbopla-
tin (NCT02264678), paclitaxel (NCT02630199), gemcitabine
(NCT03669601), olaparib (NCT02264678), acalabrutinib (NCT03328273,
NCT03527147) and durvalumab (NCT02264678), in various advanced
tumours including those with ATM-deficiency. In phase II clinical trials,
AZD6738 is currently being assessed as a monotherapy in various solid
tumours (NCT03682289), and in combinationwith olaparib in participants
with various advanced solidmalignancies (NCT02264678, NCT02576444,
NCT03682289, NCT03463342, NCT03330847, NCT03334617,
NCT03428607, and others). Also, in combination with immunotherapy,
AZD6738 plus durvalumab (anti-PD-L1 inhibitor) is currently being
assessed in advanced solid malignancies (NCT02264678), but also specif-
ically in lung cancer (NCT03334617, NCT03833440), breast cancer
(NCT03740893), refractory gastric adenocarcinoma (NCT03780608) and
metastatic melanoma (NCT03780608). As most of these clinical trials are
still on-going and recruiting, and the data from completed trials
(NCT01955668) still not reported, the full clinical potential of the drug is
yet to be revealed. That said, preliminary results for the phase I arm of a
clinical trial (NCT02264678) have been reported in conference abstracts
(Krebs et al., 2018; Yap et al., 2016). In this limited data set, AZD6738was
observed to be well-tolerated in patients in combination with carboplatin,
olaparib and durvalumab, with the most commonly reported toxicities
being thrombocytopenia, neutropenia and anaemia (for AZD6738 plus
carboplatin or plus olaparib combination), plus immune toxicities, nause-
a/vomiting, musculoskeletal chest pain and dyspnoea (for the AZD6738
plus durvalumab combination)  in 20% subjects (Krebs et al., 2018; Yap
et al., 2016). Also the preliminary pharmacokinetics data for AZD6738
revealed rapid absorption of the drug, with peak plasma concentrations
observed after 1.5 h, and an elimination half-life of 11 h. Interestingly,
although this trial primarily focused on safety and tolerability, preliminary
signals indicated that anti-tumour activity was observed in all the combi-
nations evaluated in cancer patients with advanced solid tumours. For
example, with AZD6738 plus carboplatin, 4 out of 33 patients with
advanced cervical cancer and ovarian cancers achieved partial responses
(Yap et al., 2016), and 7 of 39 patients with advanced breast, ovarian,
prostate, pancreatic and ampullary cancer also achieved 1 complete
response, 5 partial responses and 1 unconfirmed partial response with the
AZD6738 plus olaparib combination. 4 out of 21 patients with either
squamous cell carcinoma of the larynx or advanced NSCLC achieved 2
partial responses, and another patient with NSCLC achieved a confirmed
complete response with the AZD6738 plus carboplatin combination (Krebs
et al., 2018).
2.2.3. M4344 (VX-803)
M4344, formerly known as VX-803, is another orally bioactive ATR
inhibitor which was originally developed by Vertex pharmaceuticals but
has now been acquired by Merck KGaA, Germany (in addition to M6620)
for further development. M4344 is by far the most potent ATR inhibitor
reported, strongly inhibiting ATR activity both in cell free assays (ATR
IC50 ¼ 0.15 nM) and in cellular assays (ATR IC50 ¼ 8 nM), with over 100-
fold selectivity against a panel of 308 kinases, including ATR homologs
and PI3K kinases (Zenke et al., 2019). Preclinical data for M4344 has not
been extensively reported (Zenke et al., 2019), but M4334 was reported
to exhibit synergy with several DNA-damaging chemotherapeutics, PARP
and CHK1 inhibitors in a panel of 92 cancer cell lines, and has also
demonstrated tumour regression in tumour models in vivo. While M4344
has entered two phase I clinical trials as a monotherapy or in combination
with carboplatin and cisplatin for advanced solid tumours
(NCT02278250), and in combination with niraparib (a PARP inhibitor)
against PARP-resistant recurrent ovarian cancer (NCT04149145), at the
time of writing, no clinical data has been reported.
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BAY1895344 is the most recently reported potent ATR inhibitor to
have begun evaluation in the clinic (NCT03188965). It is a potent and
selective orally-administered ATR inhibitor developed by Bayer AG
(Germany) as an optimised version of BAY-937 (structure not disclosed).
BAY-937 showed promising ATR inhibition both in cell-free (IC50 ¼ 78
nM) and cellular (IC50 ¼ 360 nM) assays, with anti-tumour activity
demonstrated both in vitro and in vivo as either a single agent, or in
combination with cisplatin (Luecking et al., 2017). Issues of low aqueous
solubility, low bioavailability (rat) and more critically hERG inhibition
observed with BAY-937 hindered further development, however. Hence
the development of BAY1895344, an improved analogue with enhanced
aqueous solubility, bioavailability across species, and with an absence of
significant hERG liabilities (Luecking et al., 2017; Wengner et al., 2020).
In vitro, BAY1895344 has proved to be a highly potent ATR inhibitor both
in cell-free (IC50 ¼ 7 nM) and cellular (IC50 ¼ 36 nM) assays with
selectivity over ATR homologs; ATM (>200-fold), DNA-PK (>40-fold),
mTOR (6-fold) and PI3K (>400-fold) (Wengner et al., 2020). Interest-
ingly, despite the mTOR inhibition observed at sub-micromolar con-
centrations (IC50 ¼ 35 nM), it was observed to inhibit the
PI3K/AKT/mTOR pathway with over 60-fold selectivity compared to its
ATR inhibition. However, despite some level of ATR selectivity reported
with BAY1895344, it is the least potent and least selective of the ATR
inhibitors currently being evaluated in clinical trials (the other drugs
being M6620, AZD6738, and M4334) (Fokas et al., 2012; Foote et al.,
2018; Zenke et al., 2019).
In vitro, BAY1895344 was shown to exhibit strong antiproliferative
activity across a panel of cancer cell lines with defective DDR pathways as
a single agent, and also demonstrated profound synergetic effects in
combination with DNA-damaging agents such as cisplatin, bleomycin,
etc. and with DDR inhibitors targeting ATM, CHK1, DNA-PK, WEE1, and
PARP (Wengner et al., 2020). Interestingly, defective ATM pathways
were observed to greatly sensitise cancer cell lines to BAY1895344.
Similar observations were also reported in various tumour models in vivo,
with effective tumour growth inhibition or tumour growth delays
observed with BAY1895344 as a monotherapy and in combination with
olaparib, radiotherapy and with even hormone therapy in ovarian,
prostate, colorectal and lymphoma models at well-tolerated doses
(Wengner et al., 2020). Also, and surprisingly BAY1895344 demon-
strated superior anti-tumour efficacy in human lymphoma xenografts
compared to equivalent doses of M6620 and AZD6738, despite its rela-
tively lower potency and selectivity against ATR. This unexpected
observation was attributed to the superior pharmacokinetic properties of
BAY1895344 compared to M6620 and AZD6738: the plasma exposure of
BAY1895344 was observed to exceed the concentration levels required
for antiproliferative activity (IC50) in tumour cells, thus accounting for
this superior antitumor efficacy BAY1895344 as a monotherapy in vivo
(Wengner et al., 2020).
With this promising pre-clinical data, BAY1895344 entered its first
clinical investigation as a monotherapy in advanced solid tumours and
lymphomas (NCT03188965) in 2017. More recently another trial eval-
uating the combination with pembrolizumab (PD-1 inhibitor) has been
reported in advanced solid tumours (NCT04095273). Preliminary data
(reported in conference abstract form) has revealed dose-limiting hae-
matological toxicities associated with this agent in an on-going clinical
trial for advanced solid tumours and lymphomas (NCT03188965). In
addition, consistent with preclinical data, all patients that were observed
with responses possessed tumours with ATM loss or ATM mutations (De
Bono et al., 2019).
3. Conclusion
DDR pathways, particularly ATR-CHK1, have been demonstrated
over recent decades to play critical roles in both the development of
cancers, and their responses to classical cancer treatments, including12cytotoxic chemotherapy, radiotherapy and even immunotherapy (Woods
and Turchi, 2013; Sun et al., 2018). The search for a potent and selective
ATR inhibitor for cancer treatment has accelerated in recent times, with
several agents having entered various clinical investigations. Considering
the promising preclinical data for these agents, there remains consider-
able optimism for successful clinical outcomes in these trials. Despite this
optimism, there is also cause for caution. While the results of these
clinical trials are eagerly awaited, preliminary data seem to validate some
earlier concerns of toxicities raised with ATR inhibition as a cancer
treatment (Karnitz and Zou, 2015). Despite some promising responses,
including complete responses observed with some ATR inhibitors
currently being investigated in the clinic (Krebs et al., 2018; Yap et al.,
2016), the occurrence of dose-limiting haematological toxicities, and
treatment-emergent adverse events seem to be a common observation
with these agents, particularly when in combination with cytotoxic
chemotherapy (perhaps the most likely clinical scenario), although these
agents are well-tolerated as monotherapies, with no dose-limiting tox-
icities (Yap et al., 2015, 2016; De Bono et al., 2019). Interestingly, some
of these toxicities had been earlier observed in various preclinical set-
tings. For example, the dosing of carboplatin prior to administration of
AZD6738 was not tolerated, leading to drastic weight loss in rats, while
the reverse dosing sequence was tolerated (Clack et al., 2015). Also,
several dose-limiting toxicities were reported to be observed with
AZD6738 dosing, including changes in food consumption and body
weight in dogs, rats and mice, in addition to bone marrow toxicity,
hypocellularity in multiple lymphoid tissues and increase in alveolar
macrophages, although recovery from these toxicities was observed after
the termination of dosing (Vendetti et al., 2015). Again, the combination
of BAY1895344 with carboplatin was observed to produce
dose-dependent toxicity, which limited the potential therapeutic value of
this combination, and potentially with other Pt-based chemotherapies
(Wengner et al., 2020). It is therefore of no surprise that safety and
tolerability of different dosing schedules are now the key emphasis for
new entry ATR inhibitors (M4334 and BAY1895344) under clinical
investigation, perhaps to avoid or minimise toxicities which may likely
undermine the clinical potential of these promising ATR inhibitors.
ATR is an established essential protein whose functions are known to
be critical for both the viability and survival of cells, although these
functions are even more critical in many tumours for survival and growth
(Toledo et al., 2008; Brown and Baltimore, 2000), hence the rational for
ATR targeting as an anti-cancer therapy. However, considering the es-
sentiality of the ATR kinase and its ATR-CHK1 pathway, the “non-se-
lective” targeting of ATR may still hold the possibility to be lethal to
normal cells, leading to serious toxicity, particularly in combination with
other cytotoxic chemotherapeutics. It is worth stating that despite the
selectivity, potency and promising pre-clinical data for this generation of
ATR inhibitors, the clinical success of these agents particularly in com-
bination with chemotherapy, radiotherapy and immunotherapy will rely
on smart dosing strategies that limit the occurrence of haematological
and other toxicities. Failing that, specific targeting of these agents (e.g. as
tumour-targeted prodrugs (Gill et al., 2014; Barnieh et al., 2019)) may be
necessary, and could provide a significant opportunity to circumvent the
issues of systemic toxicity.
With the observed preliminary clinical responses reported in various
ongoing clinical investigations, particularly in patients with ATM and HR
defective tumours, the completion of these trials is likely to openmultiple
insights in the field of ATR and DDR in general.
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